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Structural and Functional 
Consequences of the 
SMA-Linked Missense Mutations 
of the Survival Motor Neuron 
Protein: A Brief Update
Wei Li
Abstract
Genetically linked to the survival motor neuron 1 gene SMN1, spinal muscular 
atrophy (SMA) is an autosomal recessive neuromuscular disease with dysfunctional  
α -motor neurons. As the product of the SMN1 gene, the survival motor neuron 
protein (SMN) plays an essential role in the molecular pathogenesis of SMA. On 1 
June 2017, a PLoS ONE article reported a set of computational structural analysis 
to illustrate how do SMA-linked mutations of SMN1 lead to structurally/function-
ally deficient variants of SMN. Following this article, this chapter provides a brief 
update of the structural and functional consequences of the missense mutations of 
this SMA protein.
Keywords: spinal muscular atrophy, survival motor neuron protein, missense 
mutation, structural consequence(s), functional consequence(s)
1. Setting the scene up
On 1 June 2017, PLoS ONE published an original research article (Figure 1) [1] 
with a title ‘How do SMA-linked mutations of SMN1 lead to structural/functional 
deficiency of the SMA protein?’, of which this chapter aims to provide a brief 
update.
1.1 The genetics of SMA: a brief introduction
SMA is an autosomal recessive neuromuscular disease with  α -motor neuron 
(anterior horn of the spinal cord) dysfunction and muscular atrophy [2]. SMA 
is caused by loss ( ∼ 95% of SMA cases) or mutation ( ∼ 5% of SMA cases) of the 
survival motor neuron gene 1 SMN1 (telomeric SMN, telSMN or SMN1, GenBank: 
U18423, the 5q13 region of human chromosome) [3]. In the 5q13 region of the 
human chromosome, there is also a nearly identical survival motor neuron 2 gene 
SMN2 (centromeric SMN, cenSMN or SMN2, GenBank: NM_022875) [3]. The two 
genes (SMN1 and SMN2) have been extensively characterised, and their roles in 
SMA have been reviewed in detail [2–8].
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1.2 The survival motor neuron protein and its role in SMA
The survival motor neuron (SMN) protein is the product of SMN1, the SMA-
determining survival motor neuron gene [2, 3]. As a result, SMN is also called the 
SMA protein. In fact, the 38-kD SMN is the actually affected protein in SMA [9–11], 
and is a cytoplasmic protein that also occurs in dot-like nuclear structures called 
gems, which is why SMN is formerly termed Gemin1 [3, 12], too.
In the molecular pathogenesis of SMA, of particular interest is an exon 7-skip-
ping splicing defect identified in the pre-mRNA editing of the SMN2 gene [5]. Due 
to this splicing defect, SMN2 predominantly produces exon 7-skipped transcripts, 
which encode a truncated isoform of the SMN protein (SMN Δ 7 or SMN2 with 282 
residues), in comparison with the full-length SMN protein with 294 residues (SMN1 
or FL-SMN).
In pre-mRNA editing, spliceosome is the major functional unit, and spliceoso-
mal small nuclear ribonucleoproteins (snRNPs) are essential components of the 
nuclear pre-mRNA processing machinery [13–17]. In the pathogenesis of SMA, the 
SMN protein plays a critical role in pre-mRNA processing, because the biogenesis of 
spliceosomal snRNPs is promoted by the SMN complex [14, 18, 19], which consists 
of SMN (Gemin1), Gemin2–8 and UNR-interacting protein (UNRIP) [13, 16, 20]. 
In the formation of the SMN complex, SMN forms oligomers and directly interacts 
via its N-terminus with Gemin2 and via its tudor domain with spliceosomal (Sm) 
proteins [13, 21, 22]. A key component of the SMN complex, SMN first assembles 
the essential SMN/Gemin complex, which in turn mediates the formation of the Sm 
core domain of the spliceosomal snRNPs [13, 21, 22].
2.  Structural and functional consequences of the SMA-linked missense 
mutations of SMN
In general, genetic mutation includes missense, nonsense, insertion and deletion 
mutations. A nonsense mutation is a point mutation in a DNA sequence that results 
in a premature stop codon, or a nonsense codon in the transcribed mRNA, and in a 
truncated, incomplete and usually functionally deficient protein product. In con-
trast, a missense mutation involves substitution of one single amino acid residue, 
and therefore is able to provide unique access to residue-specific structural insights 
Figure 1. 
A flow chart for the computational analysis of structural/functional consequences of clinically identified genetic 
diseases-linked missense mutation(s) of key gene(s) and protein(s). In [1], SMA was shown as an example of 
the computational analysis as illustrated here in this figure (http://biomedical-advances.org/ep-20182-14/).
3Structural and Functional Consequences of the SMA-Linked Missense Mutations of the Survival…
DOI: http://dx.doi.org/10.5772/intechopen.81887
into the role of the residue in the structure and function of the target protein, 
provided that the three-dimensional structure of the target protein is experimen-
tally determined and deposited in the Protein Data Bank. Thus, this chapter focuses 
on SMA-linked missense mutations of SMN and aims to provide a brief update of 
their structural and functional consequences with a set of computational structural 
analysis as described in [1].
2.1 An update of SMA-linked missense mutations of SMN
A set of point mutations (missense and nonsense mutations) have been previ-
ously summarised in [1], including A2G [23], nonsense mutation Q15X [24], D30N 
[25], D44V [25–27], V94G [28], G95R [25], Y130C [29], nonsense mutation Q157X 
[30], A188S [31], nonsense mutation W190X [32], nonsense mutation L228X [33], 
P245L [34], L260S [28], S262G and S262I [4, 25], M263T [32], S266P [29], Y272C  
[4, 35, 36], H273R [29], T274I [4, 35, 36], G275S [32], G279C and G279V [4, 35, 37, 
38]. As of 25 September 2018, eight more missense mutations of SMN were sum-
marised and reported, including A2V, Y109C, Y130C, Y130H, P221L, S230L, P244L 
and R288S [39].
2.2 An update of experimentally determined SMN-related structures
In [1], 11 SMN-related structures were retrieved from the PDB database [40] 
with 2 search parameters (text search for: survival motor neuron protein and 
molecule: survival motor neuron protein). In a new search of the PDB database 
(accessed 25 September 2018) [40] with the same parameters, 14 PDB entries were 
retrieved, including 1G5V, 1MHN, 2LEH, 4A4E, 4A4G, 4GLI, 4QQ6, 4V98, 
5XJL, 5XJQ, 5XJR, 5XJS, 5XJT and 5XJU. In a comparison with the PDB entries in 
[1], during the past 16 months, six new SMN-related structures were deposited in 
the Protein Data Bank, including 5XJL (to supersede 3S6N [41]), 5XJQ [42], 5XJR 
[42], 5XJS [42], 5XJT [42] and 5XJU [42]. While the six PDB entries do contain a 
set of different yet functionally related protein molecules, including snRNP Sm-D1, 
snRNP Sm-D2, snRNP E, snRNP F and snRNP G, they also contain a fragment of 
the survival motor neuron protein (SMN residues 26–62), according to the fasta 
format data of the six PDB entries [42].
2.3 An update of the structural and functional consequences of the missense 
mutations of SMN
2.3.1 Asp44 in the Gemin2-binding domain of SMN
In light of the six new experimentally determined SMN-related structures 
(Table 1), a new set of computational structural analysis, as previously described 
in detail in [1], is within the reach of this chapter to provide an update of it. Two 
aspartates (Asp 35 and Asp44) of SMN stood out in the structural analysis of both 
intramolecular and intermolecular salt bridges for this SMA protein, as listed in 
Table 2.
Asp44 is in the exon 2a of SMN1 (the Gemin2-binding domain), and involved 
in an SMA-linked Asp44Val (D44V) missense mutation [25], which involves a 
substitution of Asp44’s charged side chain by Val44’s hydrophobic side chain. Of 
extraordinary functional significance is that SMN’s Gemin2-binding activity is 
totally suppressed by the D44V mutation in SMN1 [41]. Moreover, the D44V SMN 
(SMND44V) mutant’s snRNP assembly activity is lower than that of the wild-type 
SMN (FL-SMN or SMN1) [27].
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In a solid alignment with the computational analysis in [1], a set of salt bridges 
were structurally identified between SMN’s Asp44 (M_Asp_44) and Gemin2’s 
Arg213 (2_Arg_213), as shown in Table 2. In particular, four intermolecular salt 
bridges were identified between the buried side chains (Table 3) of these two 
charged residues, i.e. according to the coordinates data in the PDB entry 5XJL [42], 
as shown in Figure 2.
Taken together, it is conceivable that the buried side chains of SMN’s Asp44 and 
Gemin2’s Arg213 form a salt bridge, which constitutes a favourable electrostatic 
energy contribution to the SMN-Gemin2 complex structural stability [41], and 
highlights the functionally indispensable roles of the two residues’ charged side 
chains, considering the experimental observation that the SMN-Gemin2 binding is 
abrogated by the D44V mutation [41], resulting in a functionally deficient SMA-
linked D44V SMN mutant.
In addition to the intermolecular salt bridges formed between SMN’s Asp44 and 
Gemin2’s Arg213, a set of intramolecular salt bridges were also identified between 
side chains of SMN’s Asp35 and Lys41 (Table 2), which was reported in [1], too, 
where 15 salt bridges were identified between the side chains of SMN’s Asp35 and 
Lys41 in the salt bridge analysis of the NMR-determined SMN-Gemin2 complex 
ensemble (PDB ID: 2LEH) [22, 41]. In SMN, Lys41 is a positively charged residue 
and also a neighbouring residue of Asp44. Functionally different to the SMA-linked 
D44V mutation, a Lys41Ala (K41A) mutation (not SMA-linked) does not affect 
SMN-Gemin2 binding [41]. Thus, in another solid agreement with the structural 
analysis in [1], the structural analysis highlights that the salt bridges between SMN’s 
Asp35 and Lys41 are intramolecular, i.e. within the apo SMN protein, instead of 
intermolecular, i.e. at the SMN-Gemin2 complex structure interface, which help to 
explain why the Lys41Ala (K41A) mutation is not SMA-linked [41].
Overall, there is a solid agreement between the old [1] and the new (this chap-
ter) sets of computational structural analysis for both NMR and X-ray SMN-related 
structures, reflecting the technical maturity of the two main biophysical tools 
for biomolecular structure determination, particularly in light of the booming 
number of cryo-electron microscopy (cryo-EM) images uploaded to the Electron 
PDB ID Structure title Method Release 
date
5XJL Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2 in complex with SmD1/D2/F/E/G from human
X-ray 2 May 
2018
5XJQ Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2 in complex with SmD1(1–82)/D2/F/E/G from human
X-ray 4 July 
2018
5XJR Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2dN39 in complex with SmD1(1-82)/D2/F/E/G from human
X-ray 4 July 
2018
5XJS Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2dN39 in complex with SmD1(1-82)/D2/F/E from human
X-ray 4 July 
2018
5XJT Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2 in complex with SmD1(1-82)/D2.R61A/F/E/G from 
human
X-ray 4 July 
2018
5XJU Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2dN39 in complex with SmD1(1-82)/D2.R61A/F/E/G from 
human
X-ray 4 July 
2018
In this table, X-ray represents X-ray crystallography as a biophysical tool for biomolecular structure determination.
Table 1. 
A list of new (compared with those summarised in [1]) experimentally determined SMN-related structures as 
of 25 September 2018 [40].
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Microscopy Data Bank (EMDB), where a long way is there to go still for cryo-EM to 
match NMR spectroscopy and X-ray crystallography in terms of technical maturity 
and the urgent need of tools for structural model quality validation [45].
2.3.2 Gly95 in the SMN tudor domain
Although not located in the structurally determined region of the six new struc-
tures (Table 1), Gly95 is a residue in the SMN tudor domain, and it is involved in a 
Gly95Arg (G95R) mutation [25]. This G95R mutation significantly reduces SMN’s 
ability to bind Sm proteins, such as Sm-B and Sm-D1 [25], confirming that tudor 
domain is the essential binding site of SMN to Sm proteins.
In a further inspection of the computational analysis as reported in [1], no salt 
bridge or hydrogen bond was identified for Gly95. Nonetheless, in the SMN tudor 
domain NMR ensemble [46], between the side chains of Asp96 and Lys93, 1 salt 
bridge was found for PDB ID 1G5V [46] with 10 structure models, 18 salt bridges 
PDB ID SBnum Residue A Atom A Residue B Atom B Distance (Å)
5XJL 4 M_ASP_44 OD1 2_ARG_213 NH1 2.946 (Yellow)
5XJL 4 M_ASP_44 OD1 2_ARG_213 NH2 3.579 (Red)
5XJL 4 M_ASP_44 OD2 2_ARG_213 NH1 3.236 (Brown)
5XJL 4 M_ASP_44 OD2 2_ARG_213 NH2 3.848 (Blue)
5XJQ 3 M_ASP_44 OD1 2_ARG_213 NH1 2.760
5XJQ 3 M_ASP_44 OD1 2_ARG_213 NH2 3.593
5XJQ 3 M_ASP_44 OD2 2_ARG_213 NH1 2.968
5XJR 2 M_ASP_44 OD1 2_ARG_213 NH1 2.385
5XJR 2 M_ASP_44 OD2 2_ARG_213 NH1 2.871
5XJS 3 M_ASP_44 OD1 2_ARG_213 NH1 3.078
5XJS 3 M_ASP_44 OD1 2_ARG_213 NH2 3.670
5XJS 3 M_ASP_44 OD2 2_ARG_213 NH1 2.631
5XJT 3 M_ASP_44 OD1 2_ARG_213 NH1 2.335
5XJT 3 M_ASP_44 OD1 2_ARG_213 NH2 3.386
5XJT 3 M_ASP_44 OD2 2_ARG_213 NH1 3.067
5XJU 2 M_ASP_44 OD1 2_ARG_213 NH1 2.302
5XJU 2 M_ASP_44 OD2 2_ARG_213 NH1 2.989
5XJQ 1 M_ASP_35 OD1 M_LYS_41 NZ 3.921
5XJS 2 M_ASP_35 OD1 M_LYS_41 NZ 3.670
5XJS 2 M_ASP_35 OD2 M_LYS_41 NZ 3.803
5XJT 2 M_ASP_35 OD1 M_LYS_41 NZ 2.416
XJT 2 M_ASP_35 OD2 M_LYS_41 NZ 2.931
5XJU 1 M_ASP_35 OD1 M_LYS_41 NZ 3.274
In this table, the residue naming scheme is Chain ID_residue name_residue number, SBnum represents the number 
of salt bridges computationally identified from the PDB entries listed in this table. In the top four rows for PDB entry 
5XJL, Yellow, Red, Brown and Blue represent the colouring scheme for Figure 2. Distance represents the distance 
between two oppositely charged groups/atoms in Å.
Table 2. 
A summary of salt bridge analysis of the six new SMN-related structures as of 25 September 2018 [40].
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Figure 3. 
Two salt bridges formed between the side chains of SMN’s Asp96 and Lys93 (shown as sticks here) according to 
a salt bridge analysis of the third structural model of the NMR ensemble (PDB ID 4A4E) [47]. In this figure, 
Asp96’s side chain oxygens are coloured red, and Lys93’s side chain nitrogen is coloured blue, while all hydrogen 
atoms are coloured in white.
were found for PDB ID 4A4E [47] with 20 structure models (Figure 3) and 16 salt 
bridges were found for PDB ID 4A4G [47] with 20 structure models. Similarly, 15 
salt bridges were also identified between the side chains of Glu147 and Lys97 of 
SMN (PDB ID: 4A4G [47], with 20 structure models), with the distance between 2 
oppositely charged groups being 2.93  ± 0.39 Å.
Quite interestingly, Gly95 sits right between the two oppositely charged neigh-
bouring residues (Asp96 and Lys93), which are the only two charged residues in the 
Figure 2. 
Four salt bridges formed between the buried side chains of SMN’s Asp44 (M_Asp_44 in red text) and Gemin2’s 
Arg213 (2_Arg_213 in white text). In this figure, the residue naming scheme is Chain ID_residue name_residue 
number. In this figure, Asp44’s side chain oxygens are coloured red, and Arg213’s nitrogen atoms are coloured blue, 
while all hydrogen atoms are coloured in white, the four dotted lines in four colours represent the four side chain salt 
bridges formed between the two oppositely charged residues, where the colouring scheme is described in Table 2.
Residue SASA (Å2) SASA-intrinsic (Å2) SASA-Ratio
2_Arg_213 57 238.76 0.238
M_Asp_44 67 140.39 0.477
In this table, SASA, SASA-intrinsic and SASA-ratio represent for SMN’s Asp44 and Gemin2’s Arg213 the average 
SASA value calculated by DSSP [43], the intrinsic SASA value [44] and the ratio of SASA divided by SASA-intrinsic, 
respectively. In this table, the residue naming scheme is Chain ID_residue name_residue number.
Table 3. 
Solvent accessible surface area (SASA) values of SMN’s Asp44 and Gemin2’s Arg213 (PDB ID: 5XJL) [42].
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tudor domain that are in the spatial proximity of Gly95. Thus, it is conceivable that 
a G95R mutation disrupts the Asp96-Lys93 salt bridge and/or builds another one 
(possibly even stronger) between the side chains of Lys95 and Asp96, which either 
perturbs the structure-stabilising activity of the Asp96-Lys93 salt bridge, and/or 
makes it energetically more unfavourable for Asp96’s side chain to orient towards 
positively charged side chains in Sm proteins and thereby affect the binding of 
SMN to Sm proteins. While the potential local electrostatic interaction disruption 
mechanism here for this SMA-linked G95R mutation is similar to that of the E134K 
and the Q136E mutations of SMN [1], the former mechanism is dependent on 
the occurrence of energetically unfavourable electrostatic interaction(s), but the 
latter mechanism is dependent on the loss of energetically favourable electrostatic 
interaction(s) for local structural stability of the SMN tudor domain, the essential 
part of SMN for the Sm protein-binding, which can help explain the reduced Sm 
core assembly activity of the two SMA-linked SMNE134K and SMNQ136E mutants.
2.3.3 Y109C, Y130C and Y130H in the SMN tudor domain
Among the eight SMN residues with SMA-linked missense mutations [39], 
only Y109 and Y130 are located in the structurally determined region of SMN [1], 
according to the updated list of SMN-related structures as of 25 September 2018. 
Although Y109C, Y130C and Y130H are not located in the structurally determined 
region of the six new structures, the three missense mutations are located in the 
structurally determined region of the experimentally determined structures [1].
Tyr130 is a tudor domain hydrophobic residue with a Tyr130Cys (Y130C) 
mutation [29]. In the computational analysis in [1], no salt bridge or hydrogen bond 
was identified for Tyr130. Nonetheless, Tyr130 is  ∼ 50% buried, with an  SASA value 
of 111.1  ± 4.18 Å2 compared with its standard  SASA value at 212.7 Å2, while Tyr109 
is deeply buried, with an  SASA value of 61.1  ± 8.43 Å2 compared with its standard  
SASA value at 212.7 Å2. Taken together, the SASA analysis of the three SMA-linked 
mutations highlights the potential significance of the deeply buried hydrophobic 
side chains of Tyr109 and Tyr130 in the SMN tudor domain.
PDB File Acceptor (A) Donor (D) Hydrogen (H) D-A 
(Å)
H-A 
(Å)
 ∠ADH (∗) 
0.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.73 1.80 13.75
3.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.69 1.77 15.61
4.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.67 1.72 10.96
5.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.77 1.86 17.26
6.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.71 1.78 15.09
8.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.78 1.87 16.14
12.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.83 1.95 20.70
14.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.71 1.78 13.76
18.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.71 1.76 10.91
19.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.63 1.70 13.36
In this table, the names of the PDB files correspond to the single NMR structural model split from the NMR ensemble 
(PDB entry 4A4E) by a tcl script [1], the residue naming scheme is Chain ID_residue name_residue number,  
∠ADH represents the angle formed by acceptor (A), donor (D) and hydrogen (H)  (∠ADH) .
Table 4. 
The hydrogen bonds formed between the residue side chains between SMN’s Tyr109 and Asp105 (PDB entry 
4A4E).
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What is more, in the computational analysis in [1], 10 side chain hydrogen bonds 
(Table 4) were identified between SMN’s Tyr109 and Asp105 in the PDB entry 
4A4E [47], with the donor-acceptor distances ( D − A in Table 4) at 2.72  ± 0.06 Å 
and  ∠ADH at 14.75  ± 2.93, no salt bridge was identified for Asp105, and no further 
hydrogen bonds were identified for Tyr109 and Asp105 for all experimentally 
determined SMN-related structures as of 25 September 2018.
Taken together, the computational findings here indicate that SMN’s Tyr109 and 
Asp105 contribute to the structural stability of SMN through hydrogen bonding 
between their side chains, as it is quite clear that if Tyr109 is replaced by Cys109, 
then the side chain hydrogen bond (Figure 4, Table 4) will disappear, and that the 
negatively charged side chain of Asp105 will gain more geometric freedom due to 
the disappearance of the hydrogen bond, which can cause a potential disruption of 
the (either intramolecular and/or intermolecular) electrostatic interaction network, 
not to mention the possibility of a disrupted disulphide bonding network within 
the SMN protein, the SMN complex or even the snRNP assembly, which is critical 
to ensure that pre-mRNA editing of the SMN1 gene does not go wrong and that 
its product is the FL-SMN protein, instead of its truncated functionally deficient 
counterpart.
2.3.4  A structural analysis of the hydrogen bonds formed within the six new 
SMN-related structures
In light of the six new experimentally determined SMN-related structures 
(Table 1), a new set of hydrogen bonding analysis is conducted according to the 
details in [1], the result of which is briefly summarised in Table 5.
Table 5 shows the four hydrogen bonds formed between snRNP Sm-D2’s Asp93 
and Gemin2’s Arg235 and Arg239. Functionally, Gemin2 is closely linked to SMN 
(formerly known as Gemin1), and NMR spectroscopy was used to experimentally 
determine a Gemin1-Gemin2 complex structure (PDB ID: 2LEH) [22, 41], making a 
closer visual inspection worthwhile of the SMN-related structures (PDB IDs: 5XJS, 
5XJT and 5XJU [42], Table 1).
From Figure 5 (PDB ID:5XJS), it is quite clear that the three charged residues 
(snRNP Sm-D2’s Asp93 and Gemin2’s Arg235 and Arg239) sit right at the struc-
tural interface between Sm-D2 (pink) and Gemin2 (green), with their oppositely 
Figure 4. 
The hydrogen bond (Table 4) formed between the side chains of SMN’s Tyr109 and Asp105 in the PDB entry 
4A4E [47]. In this figure, SMN’s Tyr109 and Asp105 are shown in sticks, all side chain oxygens are coloured 
red, and side chain nitrogen is coloured blue, while all hydrogen atoms are coloured in white, and all atoms are 
labelled with their names nearby. The blue dotted line between OD2 of Asp105 and HH of Tyr109 represents 
the hydrogen bond formed between SMN’s Tyr109 and Asp105.
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charged side chains closely facing each other, similar to the situation as reported 
by [1], where the deeply buried side chains of SMN’s Lys45 and Asp36 act as two 
electrostatic clips at the SMN-Gemin2 interface via interactions with both the side 
chains and the backbone of Gemin2’s Gln105, Gln109, His120, His123 and Trp124.
In the subsequent computational salt bridge analysis of the six new SMN-related 
structures, it turned out that the three charged residues did form salt bridges 
between their closely facing oppositely charged side chains, as listed in Table 6 
below and illustrated in Figure 6.
Collectively, snRNP Sm-D2’s Asp93 and Gemin2’s Arg235 and Arg239 are three 
structurally important residues which help stabilise the structural interface through 
intermolecular electrostatic interactions, including both salt bridges and also 
hydrogen bonds, similar to the way SMN’s Asp44, Gemin2’s Arg213 and the two 
SMN residues (Lys45 and Asp36) play stabilising roles in the SMN-Gemin2 complex 
structure formation [1].
Considering the intimate functional relationship between Gemin2 and SMN, a 
further set of structural analysis was conducted for the hydrogen bond and the salt 
bridge for Arg235 and Arg239 of PDB entry 2LEH [22, 41], and it turned out that 
PDB ID Acceptor (A) Donor (D) Hydrogen (H) D-A 
(Å)
H-A 
(Å)
 ∠ADH (∗) 
5XJR OE1, A_GLN_24 NH2, B_ARG_94 HH21, B_ARG_94 3.00 1.99 1.79
5XJR OD2, B_ASP_104 NH1, B_ARG_102 HH12, B_ARG_102 2.98 2.07 20.93
5XJS OD1, B_ASP_93 NE, 2_ARG_235 HE, 2_ARG_235 2.94 1.96 11.86
5XJS OD1, B_ASP_93 NH2, 2_ARG_239 HH21, 2_ARG_239 2.98 1.98 5.80
5XJS OD2, B_ASP_60 ND2, B_ASN_64 HD22, B_ASN_64 2.99 2.13 25.53
5XJT OD1, B_ASP_93 NE, 2_ARG_235 HE, 2_ARG_235 2.65 1.75 21.43
5XJU OD1, B_ASP_93 NE, 2_ARG_235 HE, 2_ARG_235 2.98 2.08 23.00
5XJU OD2, B_ASP_60 ND2, B_ASN_64 HD21, B_ASN_64 2.80 1.99 29.63
In this table, the residue naming scheme is Chain ID_residue name_residue number,  ∠ADH represents the angle 
formed by acceptor (A), donor (D) and hydrogen (H)  (∠ADH) .
Table 5. 
The hydrogen bonds formed between the residue side chains within the six new experimentally determined 
SMN-related structures.
Figure 5. 
Crystal structure of the Gemin2-binding domain of SMN, Gemin2 in complex with SmD1/D2/F/E (PDB ID: 
5XJS [42]). In this figure, the whole structure is shown in cartoon and coloured by chain using PyMol [48], 
where green and pink represent Gemin2 and snRNP Sm-D2, respectively. In this figure, three amino acid 
residues are shown in sticks and labelled with red and blue texts nearby.
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the two arginines did not form any intermolecular electrostatic interaction with 
SMN, neither salt bridge nor hydrogen bond. Instead, the 2 arginines of Gemin2 
only formed 2 hydrogen bonds with Gln272 and His231 of Gemin2, and 1 stable 
salt bridge with Asp274 of Gemin2, where 16 salt bridges were identified for the 32 
NMR structural models (Table 7), according to the structural analysis of PDB entry 
2LEH [22, 41].
PDB ID SBnum Residue A Atom A Residue B Atom B Distance (Å)
5XJL 3 B_ASP_93 OD1 2_ARG_239 NH1 3.734
5XJL 3 B_ASP_93 OD1 2_ARG_239 NH2 3.052
5XJL 3 B_ASP_93 OD2 2_ARG_239 NH2 3.052
5XJQ 3 B_ASP_93 OD1 2_ARG_239 NH1 3.817
5XJQ 3 B_ASP_93 OD1 2_ARG_239 NH2 3.059
5XJQ 3 B_ASP_93 OD2 2_ARG_239 NH2 3.004
5XJR 3 B_ASP_93 OD1 2_ARG_239 NH1 3.811
5XJR 3 B_ASP_93 OD1 2_ARG_239 NH2 3.022
5XJR 3 B_ASP_93 OD2 2_ARG_239 NH2 2.938
5XJS 3 B_ASP_93 OD1 2_ARG_239 NH1 3.688
5XJS 3 B_ASP_93 OD1 2_ARG_239 NH2 2.983
5XJS 3 B_ASP_93 OD2 2_ARG_239 NH2 3.092
5XJT 2 B_ASP_93 OD1 2_ARG_239 NH2 3.251
5XJT 2 B_ASP_93 OD2 2_ARG_239 NH2 3.163
5XJU 3 B_ASP_93 OD1 2_ARG_239 NH1 3.634
5XJU 3 B_ASP_93 OD1 2_ARG_239 NH2 3.084
5XJU 3 B_ASP_93 OD2 2_ARG_239 NH2 3.089
5XJL 2 B_ASP_93 OD1 2_ARG_235 NH2 3.657
5XJL 2 B_ASP_93 OD2 2_ARG_235 NH2 3.475
5XJQ 2 B_ASP_93 OD1 2_ARG_235 NH2 3.686
5XJQ 2 B_ASP_93 OD2 2_ARG_235 NH2 3.647
5XJR 2 B_ASP_93 OD1 2_ARG_235 NH2 3.847
5XJR 2 B_ASP_93 OD2 2_ARG_235 NH2 3.800
5XJS 2 B_ASP_93 OD1 2_ARG_235 NH2 3.548
5XJS 2 B_ASP_93 OD2 2_ARG_235 NH2 3.379
5XJT 2 B_ASP_93 OD1 2_ARG_235 NH2 3.258
5XJT 2 B_ASP_93 OD2 2_ARG_235 NH2 3.766
5XJU 1 B_ASP_93 OD1 2_ARG_235 NH2 3.996
In this table, the residue naming scheme is Chain ID_residue name_residue number, SBnum represents the number 
of salt bridges computationally identified from the PDB entries listed in this table. Distance represents the distance 
between two oppositely charged groups/atoms in Å.
Table 6. 
A summary of salt bridge analysis of the six new SMN-related structures as of 25 September 2018 [40].
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3. Concluding remarks
Given SMN’s critical role in the maturation of snRNP and in the development of 
SMA [2, 6, 11], it is necessary for the structure-activity relationship (SAR) charac-
terisation to continue for the SMA protein. With various biophysical tools available 
for structural determination, for SMN-related proteins and biological complexes, 
Figure 6. 
Crystal structure of the Gemin2-binding domain of SMN, Gemin2 in complex with SmD1/D2/F/E (PDB ID: 
5XJS) [42]. In this figure, the yellow dotted lines represent two examples of the hydrogen bonds formed between 
Asp93 and Arg235, while the blue dotted line represents an example of the salt bridge formed between Asp93 
and Arg239 (Table 6).
PDB ID SBnum Residue A Atom A Residue B Atom B Distance (Å)
24.pdb 2 A_ASP_274 OD1 A_ARG_239 NH2 3.797
24.pdb 2 A_ASP_274 OD2 A_ARG_239 NH2 2.738
01.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.577
02.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.164
04.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.195
09.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 2.692
16.pdb 1 A_ASP_274 OD2 A_ARG_235 NH1 3.871
17.pdb 1 A_ASP_274 OD2 A_ARG_235 NH1 2.868
19.pdb 1 A_ASP_274 OD2 A_ARG_235 NH1 3.718
21.pdb 2 A_ASP_274 OD2 A_ARG_235 NH1 3.457
21.pdb 2 A_ASP_274 OD2 A_ARG_235 NH2 3.429
23.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.798
24.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 2.888
26.pdb 3 A_ASP_274 OD1 A_ARG_235 NH2 3.770
26.pdb 3 A_ASP_274 OD2 A_ARG_235 NH1 3.836
26.pdb 3 A_ASP_274 OD2 A_ARG_235 NH2 2.442
31.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.403
In this table, the residue naming scheme is Chain ID_residue name_residue number, SBnum represents the number 
of salt bridges computationally identified.
Table 7. 
A summary of salt bridge analysis of PDB entry 2LEH [22, 41].
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such as the SMN complex and snRNPs, their structure determination and func-
tional characterisation will undoubtedly continue to advance, which will be helpful 
both in further understanding of SMN’s role in SMA from a molecular structural 
point of view. In practice, however, advancements do not come easy. For instance, 
although both full-length structures of FL-SMN (with 294 residues) and SMN Δ 7 
(with 282 residues) were already experimentally determined using X-ray crystal-
lography and deposited in the database (PDB IDs: 4NL6 and 4NL7), they were 
subsequently withdrawn by the author because the sample used for the structure 
determination was wrong. Otherwise, these two full-length SMN structures would 
constitute the very first step towards a comprehensive picture of the structural and 
functional insights into SMN’s role in the molecular pathogenesis SMA.
As of 25 September 2018, there is still no full-length SMN (or the SMN complex 
or the snRNP assembly) structure deposited in the wwPDB website [40], although 
it contains six new experimentally determined SMN-related structures, in addition 
to those reported in [1]. In terms of amino acid sequence, those SMN-related struc-
tures are still only SMN fragments, ranging from Gly26 to Lys51, and from Asn84 to 
Glu147. In between, there is still structurally not-determined-yet regions (referred 
to as structural gaps below) consisting of 204 SMN residues. Sixteen months have 
passed since the publication of [1], the structural gaps still remain, literally zero 
progress has been made to bridge them in spite of the six newly deposited struc-
tures, calling again [1] for further comprehensive structural determination and 
functional research for this SMA protein.
4.  A residue-specific distributional analysis of the structural gaps in the 
Protein Data Bank
As a 38-kD protein, SMN is essentially a small one in terms of molecular weight, in 
comparison with all proteins whose structures have been deposited in the Protein Data 
Bank (PDB), a primary database for experimentally determined structures of biologi-
cal molecules [40]. As discussed above, even for a protein as small as SMN, experimen-
tal structure determination does not seem simple or easy, especially when it has to be 
done in a full-length and gapless manner. Therefore, to test whether any residue-spe-
cific statistical pattern (not known yet before this chapter) exists in the structural gaps 
in the whole Protein Data Bank (accessed 25 September 2018), this chapter presents a 
set of residue-specific distributional analysis of all structural gaps throughout PDB.
While the number of experimentally determined protein structures keeps 
increasing in the PDB, with the number of cryo-EM structures [49] on the rise, 
X-ray crystallography and NMR spectroscopy remain to date the two main (Table 8) 
supplementary biophysical tools in structural biology, both with strengths and 
weaknesses [50, 51].
In PDB-format data, the atomic coordinates presented in ATOM records in a 
PDB file may not exactly match the sequence in the SEQRES records. However, 
these amino acids will often be included in the SEQRES records, since the portion 
of the chain was present during the experiment. In these cases, a ‘REMARK 465’ 
entry will be included in the header of the PDB file to identify each missing residue. 
For X-ray crystallography data, the ends of chains and mobile loops are often not 
observed in crystallographic experiments, and as a result, atomic coordinates are 
not included as ATOM records in the file, leading to the occurrence of gaps for 
structure determined by X-ray crystallography. Among currently available bio-
physical tools, NMR spectroscopy is able to provide unique access to atomic-level 
structural dynamic behaviour of protein molecules in solution under physiological 
conditions (such as temperature, pH, etc.). As a result, this chapter focuses on 
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the structural gaps within protein structures determined by NMR spectroscopy, 
and aims to test whether any residue-specific statistical pattern exists in them. 
Here, structural gaps are defined as protein fragments with residues which exist 
in the originally studied molecule as shown in the SEQRES records, but not in the 
observed structure/atomic coordinates.
As of 20 September 2018, 10,844 NMR-determined protein structures have 
been deposited in the Protein Data Bank, according to a structure search with two 
parameters (molecule type = protein, experimental method = NMR). After the 
10,844 PDB files were downloaded from the PDB website, the numbers of the total 
and the missing amino acid residues were extracted with an in-house python script 
for all proteins, as listed in Table 9.
Experimental method Proteins Nucleic acids Protein/NA complex Other Total
X-ray 121,081 1958 6257 10 129,306
NMR 10,848 1256 250 8 12,362
Electron microscopy 1750 31 623 0 2404
Other 244 4 6 13 267
Multi-method 117 5 2 1 125
Table 8. 
A summary of the number of experimentally determined biomolecular structures in PDB as of 25 September 2018.
Residue Missing no. Total no. Ratio = Missing no./Total no.
A 1782 75,627 0.023
C 152 25,777 0.00589673
E 1811 79,729 0.022
D 1390 59,908 0.023
G 3321 81,347 0.041
F 615 38,993 0.015
I 640 55,070 0.011
H 5146 26,182 0.196
K 1442 75,766 0.019
M 1203 23,652 0.050
L 1439 90,833 0.015
N 831 43,080 0.019
Q 1273 44,594 0.028
P 1518 46,205 0.032
S 3159 73,904 0.042
R 1234 52,761 0.023
T 1112 56,787 0.019
W 138 13,211 0.010
V 980 70,252 0.013
Y 626 32,905 0.019
Sum 29,812 1,066,583 0.027
Table 9. 
The numbers of the total and the missing amino acid residues in NMR-determined protein structures as of 25 
September 2018.
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Figure 7. 
A residue-specific distribution of the missing residues in NMR-determined protein structures as of 25 
September 2018. In this figure, x-axis represents the one-letter codes for amino acid residues, and y-axis 
represents the residue-specific ratio of missing versus total residues in those NMR structures. The red vertical 
line highlights histidine as a particular residue with an outstanding missing ratio.
In total, the 10,844 protein structures contains 1,066,583 amino acid residues,  
 ∼ 2.8% of which (29812) are missing, i.e. the atomic positions of the 29,841 residues 
were not experimentally determined by NMR spectroscopy, although they were 
present in the NMR sample during the structural determination process.
From Figure 7, it can be seen that for 19 residues (excluding histidine), the 
missing ratio is well below or pretty close to 5%, while the missing ratio is 19.6% for 
histidine, as shown by the blue sharp peak on Figure 7. In a statistical one sample 
t-test analysis of the 19 missing ratios, it turned out 100% acceptable ( P=1 ) that the 
average of ratio is 0.0231, and that the fitness between the 19 missing ratios and the 
red horizontal line (Figure 8) is 100% acceptable ( P=1 ), according to a statistical 
Chi-square test, as revealed by Figure 8.
While a missing ratio of 5% might be considered statistically insignificant, a 
missing ratio of 19.6% is clearly not to be ignored here, raising one obvious ques-
tion: what on earth is so special about histidine that makes it so special among the 
20 naturally occurring amino acids in this residue-specific distributional analysis of 
the structural gaps?
Similar to the other 19, histidine is a naturally occurring amino acid that is used 
in the biosynthesis of proteins. Also similar to the other 19, it contains an amino 
group (which is in the protonated ▬NH3+ form under biological conditions) and a 
carboxylic acid group (which is in the deprotonated ▬COO− form under biological 
conditions). In particular, histidine has an imidazole side chain (which is partially 
protonated), classifying it as a positively charged amino acid at physiological 
pH ( ∼ 7.4). That is, among the 20 naturally occurring amino acids, five (Arg, Lys, 
His, Glu and Asp) possess ionisable side chains. Among the five, histidine is the 
only one whose side chain has an ionisable (with an intrinsic pKa at 6.04) [52, 53] 
imidazole ring structure, which can exist in two inter-convertible tautomeric 
states. While at a pH of 7.0, the imidazole ring is mostly deprotonated (proton 
occupancy = 9.88%), at a pH of 6.0, the imidazole ring is largely protonated (proton 
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occupancy = 52.30%), as defined by the classical Henderson-Hasselbalch equation 
[50], where the positively charged imidazole ring bears two NH bonds and has a 
positive electric charge, which is equally distributed between both nitrogens. As 
the pH increases, the imidazole ring loses the positive charge, and the remaining 
proton of the neutral imidazole ring can reside on either nitrogen, giving rise to two 
tautomeric states of the histidine side chain [52, 54, 55].
To sum up, it is probable that the missing ratio of histidine is much higher than 
the other 19 because it has a special side chain with special dynamic structural and 
physicochemical properties (such as stacking interaction [56]), and with a special 
imidazole ring in constant protonation-deprotonation equilibrium [57] and two 
tautomeric states [52, 54, 55], making its NMR-observables (chemical shift for 
instance) difficult to be experimentally observed and measured by NMR spectros-
copy and structurally calculated by NMR-related software in the structural deter-
mination of proteins. To address this issue of PDB-wide structural gaps, selective 
isotope labelling of histidine residues (the side chains in particular) can be a useful 
approach in biomolecular structural determination by NMR spectroscopy, not just 
alone, but also in collaboration with other biophysical tools, not just for the special 
histidine, but also for its 19 siblings in the fundamental building block of life.
Figure 8. 
A residue-specific scatter plot of the missing residues in NMR-determined protein structures as of 25 September 
2018. In this figure, x-axis represents the one-letter codes for amino acid residues, and y-axis represents the 
residue-specific ratio of missing versus total residues in those NMR structures. The red horizontal line represents 
the average missing ratio level of the 19 residues.
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